论文部分内容阅读
已有报道,在用联合口服避孕药(OC)的妇女中,血栓栓塞疾病的发病率升高。1980年Bottiger等认为这似乎与雌激素含量有关,当服用低雌激素制剂时,血栓形成发生率下降。至于激素对血栓形成的直接影响,从未有论证。当发现遗传性抗凝血酶-Ⅱ缺乏的妇女在妊娠期或用OC时,显示出血栓栓塞危险特别高时,就考虑到是否与这一血栓形成的主要抑制剂血浆抗凝血酶-Ⅱ的浓度减少有关,但在激素诱发的周期中抗凝血酶-Ⅱ浓度减少的程度要小于正常妇女用30或50μg乙炔雌二醇时的减少程度,因此难于使抗凝血酶-Ⅱ浓度减少与OC引起血栓栓塞之间的因果关系一致。为此少数学者开始研究抑制血凝的其他主要成分——C蛋白质与
It has been reported that in women with combined oral contraceptives (OC), the incidence of thromboembolic disease is increased. In 1980, Bottiger et al. Thought it seemed to be related to estrogen levels. The incidence of thrombosis decreased when taking low estrogen preparations. As for the direct effect of hormones on thrombosis, there is no proof. When hereditary anti-thrombin-II deficiency in women during pregnancy or with OC showed particularly high risk of thromboembolism, taking into account whether the main inhibitor of this thrombosis plasma antithrombin-Ⅱ , But the extent of decrease in antithrombin-II concentration in the hormone-induced period is less than that in normal women with 30 or 50 μg ethinyl estradiol, making it difficult to reduce the antithrombin-II concentration Consistent with the causal relationship between OC-induced thromboembolism. To this end a small number of scholars began to study the other main components of inhibition of clotting - C protein and